Skip to content

Grail

US · GRAL #1873 by market cap Listed 2024
99.25 -5.59 -5.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 2.12 Expensive vs history 94th percentile
5-year average 0.85 · #11 of 41 in Diagnostics & Research
P/E ratio -12.57 Cheap vs history 6th percentile
5-year average -3.99 · forward -11.63
P/S ratio 31.28 Expensive vs history 94th percentile
5-year average 14.42 · forward 26.91 · #40 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
Grail (GRAL) 4.46B -10.76 1.82 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value145.23 Economic moatNone UncertaintyVery High

Trading 46.3% below Morningstar's fair value estimate.

Fair value

GRAIL Inc receives a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 20% discount to our quantitative fair value estimate of $145.23 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's solid growth bolsters our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. Reflecting the firm's growth is its revenue 3-year growth of 25.1%, which sits in the top 20% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are undervalued.

Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's gross margin, a core component of profitability, lies in the bottom 1% compared with peers globally. This suggests that competition is intense and profit generation could prove difficult. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.

Economic moat

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Grail discussion 0 comments

Add a comment